PharmaEngine
智 擎 生 技 製 藥

PharmEngine, Inc. 4162.TWO
3Q25 Investors' Conference
2025/11/03

ChiHsing Chang, Vice President/Spokesperson

Disclaimer

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘projects,’ ‘intends,’ ‘should,’ ‘seeks,’ ‘estimates,’ ‘future,’ or similar expressions or by discussion of, among other things, strategy, goals, plans, or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. **Pricing and product initiatives of competitors**
2. **Legislative and regulatory developments and economic conditions**
3. **Delay or inability in obtaining regulatory approvals or bringing products to market**
4. **Fluctuations in currency exchange rates and general financial market conditions**
5. **Uncertainties in the discovery, development, or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products**
6. **Increased government pricing pressures**
7. **Interruptions in production**
8. **Loss of or inability to obtain adequate protection for intellectual property rights**
9. **Litigation**
10. **Loss of key executives or other employees**
11. **Adverse publicity and news coverage**

PharmaEngine cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. PharmaEngine undertakes no obligation to update publicly or revise any forward-looking statements. Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that PharmaEngine ’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of PharmaEngine, Inc.

PharmaEngine
智 擎 生 技 製 藥

AGENDA

1. 3Q 2025 Operational Highlights
2. 3Q 2025 Operational Overview
3. R&D Pipeline
   - PEP07 (CHK1 Inhibitor)
   - PEP08 (2nd Generation PRMT5 Inhibitor)
4. Vision for 2026
5. Q&A

3Q 2025 Operational Highlights: Sustainable Growth and Enhanced Pipeline

COMMERCIAL

ONIVYDE® Indication expansion

1. Result of the application to include ONIVYDE in Taiwan's insurance reimbursement for 1L treatment for metastatic pancreatic cancer to be announced at the end of 2025.

PIPELINE

New project R&D progress accelerated

1. PEP07 Phase I clinical trials to complete dose escalation and move to expansion phase by end of 2025.
2. PEP08 Phase I clinical trial had first patient dosed in October 2025.
3. PEP09 and PEP10 meet expectations with external AI/CADD collaboration.

OPERATION

Operation with sustainable growth

1. 3Q25 cash and cash equivalents and current financial assets (>3 months time deposits) at amortized cost: NT$4.591bn.
2. Green energy ratio in our energy mix increased to 20%.

PharmaEngine
智 擎 生 技 製 藥

3Q 2025 OPERATIONAL OVERVIEW

Sales and Royalties Drive Long-term Growth

NT$(000)

Item / Year	2019	2020	2021	2022	2023	2024	3Q 2025/3Q 2024 YOY (%)
Taiwan Sales	180,389	214,828	235,469	277,594	278,547	279,990	197,200 (-7%)
Royalties from Europe and Asia	133,651	271,584	419,366	376,789	426,652	543,286	422,609 (+14%)
Milestone/Sub-license Revenue	0	569,600	0	0	62,470	1,700,028	6,521 (-89%)
Total	314,040	1,056,012	654,835	654,383	767,669	2,523,304	626,330 (-3%)

3Q 2025 Financial Results

NT$(000)	1Q-3Q 2025	1Q-3Q 2024	Amount Change	% Change
Operating revenue	626,330	644,597	(18,267)	(3%)
Operating costs	35,829	35,271	558	2%
Gross profit	590,501	609,326	(18,825)	(3%)
Sales expenses	22,359	28,251	(5,892)	(21%)
G&A expenses	71,310	73,673	(2,363)	(3%)
R&D expenses	190,331	179,817	10,514	6%
Total operating expenses	284,000	281,741	2,259	1%
Operating income	306,501	327,585	(21,084)	(6%)
Total non-operating income and expenses	35,510	63,270	(27,760)	(44%)
Income before income tax	342,011	390,855	(48,844)	(12%)
Income tax expense	85,461	58,090	27,371	47%
Profit for the period	256,550	332,765	(76,215)	(23%)
EPS (NT$)	1.79	2.32	(0.53)	(23%)

PharmaEngine
智 擎 生 技 製 藥

R&D PIPELINE

Pipeline Portfolio Focuses on Precision Oncology

Program		Indications	Lead	Preclinical	Phase I	Phase II	Phase III	Approval	Commercial Rights	Partner
ONIVYDE® (liposomal irinotecan)		1L/2L PDAC	Approval						Milestone Royalty (EU/Asia) Taiwan Sales	IPSEN Innovation for patient care
DDR & Synthetic Lethality	PEP07 (CHK1i)	AML/MCL							Global	Sentinel ONCOLOGY
		Solid tumors								
	PEP08 (PRMT5i)	MTAP-del cancers							Global	PEI Owned
	PEP09	Undisclosed							Global	Undisclosed
	PEP10	Undisclosed							Global	PEI Owned

PEP07: CHK1 is Key to Cell Survival



CHK1 is a key in cell cycle regulation and DNA damage repair. When cell DNA is damaged, CHK1 will be activated to repair DNA damage and avoid incorrect inheritance. If the damage cannot be repaired, CHK1 will promote cell apoptosis.



PEP07 inhibits CHK1 function, therefore, if cell repair and replication experience any issues, it will not be able to recover and will lead to cell apoptosis.

PEP07: A Potential Best in Class CHK1 Inhibitor

Criterion	PEP07	ACR-368 (Prexasertib)	SRA-737	BBI-355
Development Phase	Phase I	Phase II	Phase I/II	Phase I/II
Potency*				
CHK1 vs CHK2 Selectivity				
Oral Bioavailability				
BBB-Penetrating			Unknown	
Indications	AML/MCL Solid tumors	Endometrial cancer Ovarian cancer Bladder cancer	Solid tumors	Solid tumors

**Cell line model*

PEP07 Phase 1 Clinical Trial Plan

Phase I Mono — dose escalation in **hematologic cancers (first patient dosed in 2023/08)** → **Phase I Mono** — dose expansion in **AML and MCL** → **Phase I Combo** — Target: **AML and MCL**

Phase I Mono — dose escalation in advanced or metastatic **solid tumors (first patient dosed in 2024/04)** → **Phase I Mono** — dose expansion in **selected indications** → **Phase I Combo** — Target: **selected indications**

Preclinical biomarker study is ongoing for further design of clinical trials.

PEP07: Potential Indications and Number of Patients

Potential Indication	Cancer Type	2022 Incidence*
High Potential	**Acute Myeloid Leukemia (AML)**	**165,500**
	MCL	**33,323**
	Gastric Cancer	968,350
	Soft Tissue Sarcoma	42,500
	GBM	**321,476**
	SCLC	372,100
	Ovarian Cancer	324,398
	Total	**2,194,324**

* Globocan 2022

PEP07's dose expansion will focus on AML, MCL, and other selected solid tumor indications.

PEP07: Potential Markets for AML and MCL

Projected Global Market Size for AML



Projected Global Market Size for MCL



Source: Global Insight Markets, Verified Market Reports, Research and Markets, Growth Market Reports

PEP08 Mechanism of Action: Synthetic Lethality

- ✓ Unlike 1st generation PRMT5 inhibitors bind PRMT5 unselectively in both cancer cells and normal tissues, 2nd generation, MTA co-operative PRMT5 inhibitors only target to MTAP-deletion cancer cells due to the higher concentration of MTA in cancer cells.



MTAP-deleted cancer cells rely on PRMT5 function

MTAP homozygous deletion and PRMT5 inhibition cause synthetic lethality for cancer cells

PEP08: A Potential Best in Class MTA-cooperative PRMT5 Inhibitor

Criterion	PEP08	AMG-193 (AMGEN)	BMS-986504 (MRTX1719)	TNG462 (Tango)	AZ3470 (Astra Zeneca)
Development Phase	Phase I	Phase II	Phase I/II	Phase I/II	Phase I/II
Potency*					
MTAP selectivity					
BBB-penetrating					
Indication	MTAP-deleted cancers				
	Solid tumors	NSCLC	NSCLC, PDAC Mesothelioma	NSCLC PDAC	Solid tumors r/r cHL

**Viability in vitro in MTAP del cell line model*

PEP08 Monotherapy Inhibits the Growth of MTAP-Deleted Tumor Models

Pancreatic Cancer CDX



NSCLC CDX



GBM CDX



PEP07 + PEP08 Combination Delivers Synergistic Effects

Pancreatic Cancer CDX



GBM CDX



PEP08: Market Size, Potential Indications and Number of Patients





Source: Research intelo, Globocan 2022

PharmaEngine
智 擎 生 技 製 藥

VISION FOR 2026

Vision for 2026

1. Start combination clinical studies for PEP07
2. Continue Phase I clinical study enrollment for PEP08
3. Preclinical candidate nomination
4. Cooperate with AI/CADD partners to expand drug portfolio in DDR and synthetic lethality
5. Increase green energy percentage to 30% of our self-use electricity source, increase by 10% every year with the goal of reaching 70% green energy share by 2030

PharmaEngine
智 擎 生 技 製 藥

THANK YOU!